Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach (Q41295156)

29 September 2017

title

Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach (English)

1 reference

29 September 2017

1 reference

L N Ramya

1

1 reference

29 September 2017

Krishna Kanth Pulicherla

series ordinal

2

1 reference

29 September 2017

publication date

6 March 2015

1 reference

Pathology Oncology Research

29 September 2017

published in

1 reference

29 September 2017

volume

21

1 reference

29 September 2017

issue

4

1 reference

29 September 2017

page(s)

909-920

1 reference

Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Development of medium for enhanced production of glutaminase-free L-asparaginase from Pectobacterium carotovorum MTCC 1428.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Immune epitope database analysis resource (IEDB-AR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Efficient docking of peptides to proteins without prior knowledge of the binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Protein-ligand docking: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

A semiempirical free energy force field with charge-based desolvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

GROMACS: A message-passing parallel molecular dynamics implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

GROMACS 3.0: a package for molecular simulation and trajectory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-015-9912-0

Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide

21 January 2018

1 reference

12 December 2020

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

1 reference

12 December 2020

The Pfam protein families database

1 reference

12 December 2020

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

1 reference

12 December 2020

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Assessment of physical process conditions for enhanced production of novel glutaminase-free L-asparaginase from Pectobacterium carotovorum MTCC 1428

1 reference

12 December 2020

Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study

1 reference

12 December 2020

Purification, characterization and antitumor activity of L-asparaginase isolated from Pseudomonas stutzeri MB-405

1 reference

12 December 2020

A new L-asparaginase with antitumour activity?

1 reference

12 December 2020

The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations

1 reference

12 December 2020

Fitting a mixture model by expectation maximization to discover motifs in biopolymers

1 reference

12 December 2020

A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia

1 reference

12 December 2020

Probing the antigenicity of E. coli L-asparaginase by mutational analysis.

1 reference

12 December 2020

Circumventing immunogenicity in the development of therapeutic antibodies

1 reference

12 December 2020

Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase

1 reference

12 December 2020

The significance of lysosomes in pathology and medicine

1 reference

12 December 2020

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

1 reference

12 December 2020

In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia

1 reference

12 December 2020

Probing the role of threonine and serine residues of E. coli asparaginase II by site-specific mutagenesis

1 reference

12 December 2020

10.1007/S12253-015-9912-0

Identifiers

DOI

1 reference

29 September 2017

1 reference